Time Restricted Eating to Mitigate Obesity in Veterans With Spinal Cord Injury

Spinal cord injury (SCI) causes paralysis and muscle atrophy and leads to weight gain and obesity. Obesity directly contributes to functional impairment and cardiometabolic dysfunction. There is a critical need to reduce the growing prevalence of obesity and cardiometabolic disease after SCI. My overall objective in this project is to gather crucial feasibility data on time restricted eating (TRE), a novel form of intermittent fasting. TRE is a straightforward method to induce weight loss without the need for calorie counting. TRE allows individuals to eat all their daily calories in a time restricted window and fast outside that window. A growing body of literature supports the safety and efficacy of TRE. Given the feasibility, high adherence, and substantial benefits of TRE in able-bodied individuals, it is important to test TRE to determine its feasibility in Veterans with SCI. The investigators will first test this intervention in Veterans with paraplegia, who are at greatest risk of muscle-joint upper body injury given the need to support body weight during activity. The investigators will determine adherence to a TRE window for 6-weeks duration in a convenience sample of Veterans with paraplegia and obesity. Based on the expected outcomes of good adherence, this study will lay the groundwork for future work by informing the design of a randomized controlled trial to test the efficacy of TRE to facilitate weight loss and improve function.

Study Overview

• Status: Active, not recruiting
• Conditions: Obesity; Spinal Cord Injury
• Intervention / Treatment: Behavioral: Time Restricted Eating

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • New York
    • Syracuse, New York, United States, 13210-2716
      • Syracuse VA Medical Center, Syracuse, NY

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Veteran
• A member of the Spinal Cord Injury/Disorder (SCI/D) registry through the Syracuse VA, including both hub and spoke sites
• A qualifying diagnosis of SCI within the SCI/D registry
• Neurologic level of injury from T1 to S5, based on most recent Status Update or American Spinal Injury Association Impairment Scale (ASIA) examination, or a diagnosis of a hereditary form of paraplegia (such as familial spastic paraplegia or hereditary spastic paraplegia)
• ASIA Impairment Scale grade A-D
• Chronic SCI (> 1 year from date of SCI or diagnosis of SCI)
• BMI > 22 - the BMI used to diagnose obesity in individuals with SCI
• Mean eating window of at least 10 hours per day

Exclusion Criteria:

• Females who are pregnant (tested via urinary human chorionic gonadotropin (hCG)), planning to become pregnant in the next 6 months, or breast-feeding
• A member of the SCI/D registry through the Syracuse VA, with a qualifying diagnosis of MS or ALS
• Diagnosis of heart failure
• Diagnosis of diabetes mellitus, type 1

• Diagnosis of diabetes mellitus, type 2, and on insulin or other antidiabetic agent with high incidence of hypoglycemia

  o Of note, antidiabetic agents with low incidence of hypoglycemia are: metformin, Glucagon-like peptide-1 (GLP-1) receptor agonists, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, Dipeptidyl peptidase 4 (DPP-4) inhibitors, alpha glucosidase inhibitors, thiazolidinediones (as discussed with VA pharmacist)

• Diagnosis of End Stage Renal Disease
• Diagnosis of dementia
• Diagnosis of orthostatic hypotension and prescribed midodrine or fludrocortisone
• History of syncopal episode in the month prior to the study
• History of significant weight loss (> 10% body weight) in the month prior to the study
• History of eating disorders (e.g., anorexia or bulimia) within the last five years, or clearance from a mental health provider
• History of active suicidal ideation in the last six months, or clearance from a mental health provider
• Currently prescribed weight loss medication (e.g., liraglutide)
• Currently prescribed corticosteroids
• Current acute medical issues including cancer, sepsis, advanced liver failure, porphyria, or uncontrolled hyperthyroidism

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Time Restricted Eating; This is a single-arm study in a convenience sample of Veterans with paraplegia and obesity. The intervention will test adherence of participants to a TRE window with a self-selected start time. The duration of the eating window will be 10 hours, maintained through study's end (end of week 6).

Behavioral: Time Restricted Eating; Time Restricted Eating Protocol: Subjects will be instructed to limit caloric consumption to a 10-hour TRE window. The window start-time will be self-selected (individualized). During the eating window, subjects will not be restricted on types or quantities of food consumed, and will be advised to continue their usual diets. Subjects will not be required to monitor their caloric intake. During the fasting period, subjects will be encouraged to stay hydrated and drink ample water. Outside the designated eating window, subjects are only permitted to consume medication, water, or zero-calorie herbal drinks such as unsweetened tea or black coffee.; Other Names: TRE

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the daily eating window	Measured by questionnaire (assesses the time the participant started and stopped eating each day)	Measured weekly from baseline to week 6

Collaborators and Investigators

• Sponsor: VA Office of Research and Development
• Investigators: Principal Investigator: Geoffrey V Henderson, MD, Syracuse VA Medical Center, Syracuse, NY

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2023
• Primary Completion (Actual): July 1, 2026
• Study Completion (Estimated): August 10, 2027

Study Registration Dates

• First Submitted: June 7, 2023
• First Submitted That Met QC Criteria: June 16, 2023
• First Posted (Actual): June 27, 2023

Study Record Updates

• Last Update Posted (Actual): September 2, 2026
• Last Update Submitted That Met QC Criteria: August 28, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Wounds and Injuries; Nutrition Disorders; Overnutrition; Body Weight; Overweight; Trauma, Nervous System; Spinal Cord Diseases; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity; Spinal Cord Injuries
• Other Study ID Numbers: B4538-M; 1IK1RX004538-01A1 (U.S. NIH Grant/Contract: VA RR&D)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: A de-identified, anonymized dataset will be created and shared upon written request for appropriate scientific reasons.
• IPD Sharing Time Frame: The dataset will be available following publication of the primary manuscript for this project.
• IPD Sharing Access Criteria: The dataset will be released upon written request for scientific purposes including re-analysis and validation of results.
• IPD Sharing Supporting Information Type: SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No